Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
833.7 DKK | -4.46% | -1.51% | +7.98% |
07:34am | Coloplast Posts Higher Fiscal H1 Net Profit, Revenue | MT |
Feb. 27 | Certain B Shares of Coloplast A/S are subject to a Lock-Up Agreement Ending on 27-FEB-2024. | CI |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 36.58 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.98% | 28.33B | B+ | ||
-29.70% | 3.15B | B- | ||
-14.71% | 2.57B | C+ | ||
+21.58% | 2.55B | - | A- | |
+7.41% | 2.09B | B | ||
-3.87% | 2.04B | - | ||
+0.56% | 1.53B | B | ||
+2.15% | 1.33B | - | ||
+23.78% | 1.23B | C | ||
+4.72% | 1.16B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- COLO B Stock
- Ratings Coloplast A/S